EKTAH

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

No changes recorded yet. Missing observations do not mean the company has not changed.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

1. Seen November 2026 · 1 capture · latest observed messagingRestoring the biology of satiety

   EktaH est une start-up DeepTech de biotechnologies qui ambitionne de devenir un leader des approches thérapeutiques destinées à réduire la prise de poids corporel.

   This wording observed 10 November 2026.

   current websiteHistorical capture not publicly available
2. September 2021 – June 2022 · 3 capturesACCUEIL - EktaH

   EktaH est une start-up française de la Deeptech - Nouvelles solutions nutritionnelles pour réduire le poids corporel.​

   This wording observed 25 June 2022.

   archived page
   Inspect 3 captures in this group

   • 22 September 2021 · ACCUEIL - EktaH archived page
   • 1 January 2022 · ACCUEIL - EktaH archived page
   • 25 June 2022 · ACCUEIL - EktaH archived page

Companies in the same space

Competitors picked by an AI model from the funded startups with the most similar descriptions, judged on those descriptions only. A reading, not a verified market map.

• Ambrosia Biosciences ambrosiabiosciences.comDirect competitorBoth develop oral small-molecule therapies for obesity and metabolic disease.
• CORXEL Pharmaceuticals corxel-bio.comDirect competitorBoth are biotechs developing oral small-molecule drugs for obesity treatment.
• CORXEL (Corxel Pharmaceuticals) corxelbio.comDirect competitorBoth focus on oral small-molecule cardiometabolic therapies including obesity.
• MitoRx Therapeutics mitorxtherapeutics.comDirect competitorBoth are biotechs creating small-molecule drugs to treat obesity and related disease.
• Alveus Therapeutics alveustx.comPartial overlapBoth target obesity and metabolic disease with next-generation therapeutics.
• Antag Therapeutics antagtx.comPartial overlapBoth pursue novel therapeutic mechanisms to treat obesity and overweight.
• Pep2Tango Therapeutics pep2tango.comPartial overlapBoth develop pharmacological therapies intended for obesity and related disorders.
• Kailera Therapeutics kailera.comPartial overlapBoth work on drug-based obesity treatments including oral therapeutic options.